Boston Scientific Corporation
) recently announced the receipt of CE Mark approval in Europe
for the WallFlex Esophageal Fully Covered Stent. The device has
been designed to treat refractory benign esophageal strictures.
BAXTER INTL (BAX): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis
NUVASIVE INC (NUVA): Free Stock Analysis
To read this article on Zacks.com click here.
Both fully-covered and partially-covered WallFlex Esophageal
Stents have previously received CE Mark and U.S. Food and Drug
Administration (FDA) clearance for the palliative treatment of
malignant esophageal strictures. However, WallFlex
Esophageal Stents do not have the approval for removal from
malignant strictures. They are also not sanctioned in the U.S.
for the treatment of refractory benign esophageal strictures.
Benign or noncancerous esophageal stricture is a condition
characterized by narrowing of the esophagus by scar tissue.
Though not malignant, it can cause problems in swallowing and
increase choking risks. The primary treatment of the condition is
dilation of the esophagus that may have to be repeated after
The WallFlex Esophageal Stent from Boston Scientific is designed
for gradual expansion and is combined with a Permalumesilicone
coating that helps to prevent tumor in-growth, seal concurrent
esophageal fistulas and also help reduce food impaction.
Further, the Teflon coated polyester suture of the WallFlex
Esophageal Stent from Boston Scientific facilitates removal from
refractory benign strictures for upto eight weeks. This feature
is particularly helpful for patients as they have to make less
number of hospital visits to undertake additional dilations to
treat their stricture.
The WallFlex Stent from Boston Scientific offers physicians clear
visualization during fluoroscopy, guaranteeing correct placement
of the device during the treatment process. Moreover, its
small profile and radiopacity facilitate accurate placement
making stent removal easy and safe for healthcare experts.
The CE Mark approval of the WallFlex Fully Covered Stent of
Boston Scientific comes as welcome news for physicians in the
European Union who are involved in the treatment of benign
The commercial availability of Boston Scientific's WallFlex Stent
in the European market promises fresher avenues for revenue
growth in the near future.
Currently, Boston Scientific carries a Zacks Rank #3 (Hold).
Investors interested in the medical products industry can also
look at other stocks like
Baxter International Inc
). While NUVA carries a Zacks Rank #1 (Strong Buy), COV and BAX
hold a Zacks Rank #2 (Buy).